Possible protective effect of Moringa oleifera leaf extract on dexamethasone induced histological changes in adlt rat testes

Dexamethasone [Dex] is a widely used therapeutic agent for its immunosuppressive and anti-inflammatory action. It has adverse effects on many body organs and systems. Moringa oleifera is an antioxidant-rich natural plant. It contains vitamins C and A, and various phenolic compounds. The present study was designed to evaluate the ability of M. oleifera leaf extract to protect rat testis against Dex-induced spermatogenic defects. Thirty adult male rats were divided equally into three groups [10 animals each]: the control group [group I] and two experimental groups [groups II and III]. Rats of group II were subjected to intraperitoneal injection of 7mg/kg/day of Dex for 10 days. In group III the rats were treated with M. oleifera leaf extract at 400mg/kg/day, and then after 2h they were administered an intraperitoneal injection of Dex with the same dose as for group II for 10 days. The testes were dissected out and processed for light and electron microscope examination. Microscopic examination revealed that most of the seminiferous tubules of group II were lined with germ cells with dark pyknotic nuclei and vacuolated cytoplasm. The lumen of some tubules was obliterated with exfoliated and sometimes multinucleated giant cells. There was statistically highly significant increase in the percentage of sperm abnormality. Degenerated interstitial Leydig cells were also observed. However, in the moringa-treated group, the histological changes were reduced and the percentage of sperm abnormality was more or less similar to that of the control group. These results demonstrated that M. oleifera leaf extract has a potent protective effect against the testicular toxicity induced by Dex and hence might be clinically useful

Haemochromatosis gene mutation H63D is a risk factor for iron overload in Egyptian beta- thalassemic children

Iron overload is the main cause of morbidity and mortality in patients with beta-thalassemia. The aim of this study was to evaluate the prevalence of genetic markers [HFE mutations C282Y and H63D] among Egyptian beta-thalassemic Children and its effect on their iron status. 59 beta-thalassemic children attending the pediatric hematology clinic in Menoufiya University Hospital [23 thalassemia major, 23 thalassemia intermedia and13 thalassemia trait] with 50 apparently healthy, Egyptian children [control group] were screened for the prevalence of these two mutations by digestion of PCR products [RFLP]. Serum ferritin level was measured by ELISA. Neither carrier status for the C282Y allele nor homozygous status for the H63D allele were detected in any of the thalassemic children or the 50 controls. The H63D heterozygous state was detected in 15 [25.4%] thalassemic patients with an allele frequency of 12.71% and in 11 [22%] controls with an allele frequency of 11%. with no significant difference between the thalassemic groups and the controls. The prevalence of carriers for the H63D mutation was 26.1% with an allele frequency of 13.04% in patients with either beta- thalassemia major or intermedia, while in beta- thalassemia trait the prevalence of this mutation was 23.1% with an allele frequency of 11.54%. There were significant higher levels of the mean yearly serum ferritin in both beta-thalassemia major and intermedia patients who are heterozygotes for the H63D mutation compared to those without this mutation. The mean serum ferritin levels were positively correlated with the age of the patients. On the other hand, the prevalence of iron -induced complications was not statistically different between patients carrying or not carrying this mutation [among TM and TI]. There is no difference in the prevalence of H63D mutation between beta-thalassemic patients and the normal children and the presence of a heterozygous H63D status and older age are two risk factors for iron overload in Egyptian beta-thalassemic children. RFLP= Restriction Fragment Length Polymorphism, HCV=Hepatitis C Virus, ALT = Alanine aminotransferase, AST =Aspartate aminotransferase

Minimally invasive video assisted thyroidectomy for small follicular thyroid nodules

Minimal access surgery in the thyroid compartment has evolved considerably over the past 10 years and now takes many forms. This study examined the feasibility and reliability of minimally invasive thyroid surgery in the management of small benign thyroid lesions. Sixty eight patients with small thyroid nodules admitted in Oncology Center, Mansoura University, Egypt, were enrolled in this prospective randomized trial. Patients were allotted in one of these procedures, minimally invasive video assisted thyroidectomy [MIVAT], or minimally invasive open thyroidectomy using the Sofferman technique of strap muscle transection. Exclusion criteria were nodules greater than 4 cm, presence of thyroiditis, and thyroid gland volume greater than 20 ml Preoperative diagnosis, operative time, blood loss, postoperative pain, complications and cosmetic outcome were all evaluated. MIVAT group included 35 patients and the Sofferman group included 33 patients. The main preoperative pathology was benign follicular lesion [70.5%] and the main postoperative final pathology was follicular adenoma [54.4]. Both groups were comparable regarding age, sex and extent of thyroid surgery. Operative time was significantly longer in MIVAT group [115.4 +/- 33.5 min] compared to the Sofferman group [65.6 +/- 23.7 min]. Postoperative course was significantly less painful in MIVAT group [P< 0.05]. Although patients in MIVAT group had smaller incisions [P <0.05], the cosmetic outcome in both groups was comparable. No long term complication was encountered in both groups. Two distinct approaches of minimally invasive thyroidectomy are now available and can be performed safely in selected patients. Despite some MIVAT advantages of less postoperative pain and slightly better cosmesis, minimally invasive open thyroidectomy offers an advantage of less operative time with comparable cosmetic results

Fragile X syndrome: a clinico-genetic study of mentally retarded patients in Kuwait

In a prospective study in Kuwait, 182 mentally retarded male patients who fulfilled 5 or more clinical criteria of fragile X syndrome were screened using polymerase chain reaction [PCR] testing. Twenty patients [11%] were highly suspected of having fragile X syndrome due to mutation at the FRAXA locus; none had mutation at the FRAXE locus. Of these, 11 [55%] were confirmed fragile-X-positive by both cytogenetic and PCR techniques. The most frequent clinical features were: prominent forehead, high arched palate, hyperextensible joints, long ears, prominent jaw, height > 10th centile and attention-deficit hyperactivity. Less common were avoidance of eye contact [45%], autism [45%] and seizures [30%]. Large testes were found in 55% of cases. Pre-pubertal and post-pubertal clinical criteria were different